Human adipose stem cell differentiation is highly affected by cancer cells both in vitro and in vivo: implication for autologous fat grafting
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Recent studies showed that mesenchymal stem cells derived from adipose tissue can promote tumour progression, raising some concerns regarding their use in regenerative medicine. In this context, we co-cultured either SAOS2 osteosarcoma or MCF7 breast cancer cells with human adipose stem cells (hASCs), in order to evaluate potential effects of cancer cells on hASCs differentiation, in vitro and in vivo. In this study we observed that both SAOS2 and MCF7 cell lines induced an increase in hASCs proliferation, compared to hASCs alone, but, surprisingly, neither changes in the expression of CD90, CD29, CD324 and vimentin, nor variations in the Twist and Slug mRNAs were detectable. Noteworthy, SAOS2 and MCF7 cells induced in hASCs an upregulation of CD34 expression and stemness genes, including OCT3/4, Nanog, Sox2 and leptin, and a decrease in angiogenic factors, including CD31, PDGF α, PDGFR α, PDGFR β and VEGF. SMAD and pSMAD2/3 increased only in hASCs alone. After 21 days of co-culture, hASCs differentiated both in adipocytes and endothelial cells. Moreover, co-injection of MCF7 cells with hASCs led to the formation of a highly vascularized tumour. Taken together our findings suggest that mesenchymal stem cells, under tumour cell induction, do not differentiate in vitro or facilitate the angiogenesis of the tumour in vivo, thus opening interesting new scenarios in the relationship between cancer and stem cells. These findings may also lead to greater caution, when managing autologous fat grafts in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Zimmerlin, L., Donnenberg, A. D., Rubin, J. P., Basse, P., Landreneau, R. J., & Donnenberg, V. S. (2011) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0248 · Cited by 225 · cited 1×
“However, the risks linked to cell treatment still remain unclear, particularly in the context of patients affected by pre-existing cancer.(26,27) MSCs derived from adipose tissue could serve as a primary MSC source for cancer contributing to the tumour microenvironment and thus playing a role both in epithelial and me…”
Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120 · cited 1×
“In fact, although hASCs demonstrated good aesthetic results, they could be promoters of cancer recurrence.(22,23)”
Regenerative therapy after cancer: what are the risks?
Donnenberg, V. S., Zimmerlin, L., Rubin, J. P., & Donnenberg, A. D. (2010) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2010.0352 · Cited by 95
Cited by
Arneth, B. (2019) · Medicina · doi:10.3390/medicina56010015 · Cited by 1,250
Papaccio, F., Paino, F., Regad, T., Papaccio, G., Desiderio, V., & Tirino, V. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0138 · Cited by 292
Self-citationMesenchymal stroma: Role in osteosarcoma progression
Cortini, M., Avnet, S., & Baldini, N. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.024 · Cited by 171
Zheng, Y., Wang, G., Chen, R., Hua, Y., & Cai, Z. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0780-x · Cited by 127
New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma
Chang, X., Ma, Z., Zhu, G., Lu, Y., & Yang, J. (2021) · Journal of Bone Oncology · doi:10.1016/j.jbo.2021.100372 · Cited by 70
Mesenchymal Stem Cells and Extracellular Vesicles in Osteosarcoma Pathogenesis and Therapy
Sarhadi, V. K., Daddali, R., & Seppänen-Kaijansinkko, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011035 · Cited by 63
“OS cells (Saos–2 cell line) downregulate the expression of angiogenic factors, such as CD34, PDGFA, PDGFRA, PDGFRB, and VEGF, in human AD-MSCs when co-cultured, implying that MSCs cannot differentiate in vitro under the induction of tumor cells and do not support tumor angiogenesis in vivo [60].”
Metadata
- Authors
- Paino, F., La Noce, M., Di Nucci, D., Nicoletti, G. F., Salzillo, R., De Rosa, A., Ferraro, G. A., Papaccio, G., Desiderio, V., & Tirino, V.
- Venue
- Cell Death & Disease
- Published
- 2017-01-19
- Volume
- 8
- Issue
- 1
- Pages
- e2568-e2568
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2578095037
- Cited by
- 79
- References
- 5
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.